## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of: Kathleen SMITH, et al.

Serial No.: To be assigned Art Unit: To be assigned Filing Date: Concurrently Herewith Examiner: To be assigned

For: GENERATION OF RECOMBINANT GENES IN SACCHAROMYCES CEREVISIAE

**Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

		ts request that the references identified on Form PTO-1449 appended hereto be considered by the Examine ially made of record in accordance with the provisions of 37 CFR 1.97						
	[ ] [X]	Copies of the following references are enclosed.  Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d))  A copy of the International Search Report which issued on International Application No.  PCT/EP2005/000841 is submitted herewith. All of the publications cited in the International Search  Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.						
Α.	[X]	[X] The Information Disclosure Statement submitted herewith is being filed within three months of filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occlast. 37 CFR 1.97(b).						
	OR							
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).						
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, whichever occurs first.						
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.						
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).						

## 10/587651 (AP20 Rec'd PCT/PTO 28 JUL 2006)

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under					
		1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the					
		issue fee. Also enclosed is a copy of the International Search Report which Issued on International					
		Publication No.					

In accordance with the requirements of 37 CFR 1.97(d):

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [ ] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [X] A duplicate copy of this paper is attached.

Respectfully Submitted,

Frank P. Grassler, Attorney of Record

Registration No. 31,164

Date: July 28, 2006 GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2482 Facsimile: (919) 483-5730

## IAP20 Res'e Patritto 28 JUL 2006

C.	[ ] The Information Disclosure Statement transmitted herewith is being filed after a final action unde 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of th issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.							
	In accordance with the requirements of 37 CFR 1.97(d):							
	[ ]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]						
	[	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and						
	[	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.						
[X	] Please	charge any required fees to Deposit Account No.07-1392.						

Respectfully Submitted,

Frank P. Grassler, Attorney of Record

Registration No. 31,164

Date: July 28, 2006 GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

[X] A duplicate copy of this paper is attached.

Telephone: (919) 483-2482 Facsimile: (919) 483-5730

Page 1 of 1

FORM PTO-14 INFORMATIO	49 N DISCLOSURE ST	TATEMENT		ATTORNEY DOCKET NO. PLP573		SERVADO/651 To be assigned		
				APPLICANT: Kathleen SMITH, et al.				
				FILING DATE:		GROUP	<del></del>	
				Concurrently Here	with	To be assigned	<u>d</u>	
		U.S. P	ATENT D	OCUMENTS	1		<del></del> _	
Examiner Initials	Patent I Issue Date		Name		Class	Subclass	Filing Date If Appropriate	
							ļ	
						<del>-</del>		
	<del></del>		+		<u></u>		<u> </u>	
		1			-		<u> </u>	
							<u> </u>	
			ontinue on					
<u> </u>	Document	Publication	N PAIEN	T DOCUMENTS		1		
	Number	Date		Country	Class	Subclass	Translation Yes   No	
						<u> </u>		
			<u> </u>					
	OTHER BOCH		ontinue on		Dogo Namel	E4a)		
	Paluh, J.L., "Muta	ational Analysis of	the Gene f	, Title, Journal-Date for .Schizosaccaromy Canavanine," YEAS	ces Pombe R	NASE MPR RNA	A, MRPL, I. 12, no. 14,	
	1. November 1996,	November 1996, pp. 1393-1405.						
:	in yeast: statistic	Abecassis, V., et al., "High efficiency family shuffling based on multi-step PCR and in vivo DNA recombination in yeast: statistical and functional analysis of a combinatorial library between human cytochrome P450 A1A and 1A2," NUCLEAIC ACIDS RESEARCH, vol. 28, no. 20, October 15, 2000, pp. E88-E88.						
· ·							·	
				•				
		_					_	
				<u></u>				
			Continue on	nage				
EXAMINER			. chimae on	<u> </u>	DATE C	ONSIDERED		
	nitial if citation consider						ough citation	